Navigation Links
Research shows treating HIV-AIDS with interleukin-2 is ineffective
Date:10/15/2009

This release is available in French.

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped. Their finding was published in the New England Journal of Medicine in an article co-authored by 14 researchers, including Dr. Jean-Pierre Routy of the Research Institute of the McGill University Health Centre (RI-MUHC).

IL-2 is currently used as a complement to highly active antiretroviral therapy (known as HAART), which is administered to patients with HIV-AIDS. Since HAART controls replication of viruses in the blood, doctors thought that IL-2 would help regenerate more CD4+ immune cells, which serve as an indicator of viral progression. It was thought that IL-2 increased the natural immunity of patients by helping immune cells mature and multiply.

"Our results show that IL-2 has no effect on the development of AIDS or on patient survival," says Dr. Routy. "More precisely, while the presence of IL-2 leads to a faster increase of CD4+ immune cells, these cells are less functional than the CD4+ cells that regenerate naturally in patients who do not receive IL-2. This means that IL-2 treatment provides no benefit and does not prevent AIDS-related infectious diseases."

"For the first time, a study has shed light on recurring questions concerning the value of biological markers and their limitations in assessing patient health," explains Dr. Routy. "Our challenge now will be to develop tests that assess the function of immune cells and not simply their quantity. This will ensure that HIV treatments indeed have a clinical benefit for patients."

This 8-year study involved over 5000 patients in 25 countries, and was one of the largest ever conducted on HIV-AIDS. "The fact that data fr
'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Page: 1 2

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... by the Red Queen in Lewis Carroll,s Through ... Illinois and National University of Singapore improved a ... evolve over decades to millions of years. , ... for competition, incorporates the "Red Queen Effect," an ... the 1970s, which suggests that organisms must constantly ...
(Date:7/30/2014)... octopus protected and tended her eggs until they hatched ... 30, 2014 in the open-access journal PLOS ONE ... Institute and colleagues. , Octopuses typically have a single ... and take care of their fertilized eggs until they ... 1 to 3 months, but little is known about ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... are closing in on finding an effective bait to ... beetle, which is now killing not only lodgepole pine ... and Canada Research Chair in Forest Entomology in the ... investigating pheromones emitted by the pest in North America,s ...
... of New England (Australia) and the Royal Botanic Gardens ... species of sedge from south-western Tasmania. A small clumping ... mountains including Mount Field and Mount Sprent. It is ... essentially restricted to alpine vegetation. At less than seven ...
... professor is developing a comprehensive data system that can ... by providing them with access to chemical toxicity information. ... is building the "automated profiling system" from existing bioassay ... profiles can help scientists who are seeking information on ...
Cached Biology News:Bait research focused on outsmarting destructive beetle 2Tasmania home to first alpine sword-sedge 2Toxicity database under development at Rutgers-Camden 2
(Date:7/30/2014)... , July 30, 2014   Wyle ... Fully Integrated Lifecycle Mission Support Services (FILMSS) contract ... (NASA). Under the terms of the contract, Wyle ... at Moffett Field, Calif. In particular, Wyle will ... flight development projects on the International Space Station ...
(Date:7/30/2014)... STONY BROOK, NY (PRWEB) July 30, 2014 ... (OTCQB: APDN), (Twitter: @APDN), a biotechnology firm that provides ... Dr. Michael E. Hogan, Ph.D. Vice President of Life ... in mid-September. , Dr. Hogan will lead ... to form business relationships with biotech and healthcare customers, ...
(Date:7/30/2014)... PA (PRWEB) July 30, 2014 Vycom ... family of products, designed to meet Factory Mutual (FM) ... equipment materials such as wet benches, process tools, fume ... worker safety and damage to semiconductor wafers used in ... provides a flame-retardant PVC solution with excellent workability and ...
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... GAMMAGARD LIQUID and GAMMAGARD S/D, [Immune Globulin Intravenous ... Ill., Aug. 22 Baxter International,Inc. (NYSE: ... GARDian, an innovative,program that helps provide continued access ... [Immune Globulin Intravenous (Human)],(IGIV). IGIV products like GAMMAGARD ...
... 22 ATS Medical, Inc.,(Nasdaq: ATSI ), ... services, today announced that the US Food and ... begin marketing,additional sizes of its line of ATS ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) Michael Dale, Chairman and Chief ...
... New Ballot Initiative to Pursue Cures for Patients, ... without involving controversial Human Cloning, WASHINGTON, Aug. 22 ... ensure that taxpayer funds,support cures for patients, without involving human ... issued the,following statement on the new initiative, Cures Without Cloning. ...
Cached Biology Technology:Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 2Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 3Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 4Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 5Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 6Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 7Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 8Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 9ATS Medical Expands Open Pivot Heart Valve Offerings 2